Today’s guest post is from Reed Smith’s Matt Jacobson. He addresses the latest and greatest result from litigation that has been generating favorable decisions nationwide applying various states’ so-called “blood shield” statutes (practically every state has one) that declare the use of human cells or tissue in medical treatment to be services rather than products, which has the effect of limiting liability to negligence. As always our guest posters deserve 100% of the credit (and any blame) for their work.
**********
Milovich v. Aziyo Biologics, Inc., No. 1:24-cv-01208-CL, 2025 U.S. Dist. LEXIS 50935 (D. Or. Feb. 24, 2025), involves Oregon’s human blood and tissue shield statute. The Drug & Device Law Blog has written about similar cases before, but this one might be the best. Blood shield laws have been around for over 60 years. They sound like something that Dracula should fear, along with a knife through the heart, the sun, holy objects, and garlic. But they are not something that should scare anyone who manufactures blood or tissue based products. While states have different statutory language, the gist of blood shield laws is that blood transfusions and transplants are a service and not a sale (Dracula would agree he is performing a service), thus barring claims for breach of warranty and strict liability.Continue Reading Guest Post – The Sun Is Not Setting on Oregon’s Blood Shield Statute